Journal of Pharmacogenomics & Pharmacoproteomics

Epigenetic in lung cancer

7^th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics

October 05-06, 2017 Chicago, USA

Seyedeh Afrooz Azimi

Mashhad University, Iran

Scientific Tracks Abstracts: J Pharmacogenomics Pharmacoproteomics

Abstract:

The concepts of personalized medicine can be applied to new and transformative approaches in health care. Epigenetic is based on the dynamics of system biology and uses predictive tools to evaluate health risks and to design personalized health plans to help patients mitigate risks, prevent disease and to treat it with precision when it occurs. Every person has a unique variation of the human genome. Although most of the variation between individuals has no effect on health, an individual's health stems from genetic variation with behaviors and influences from the environment and epignetic can also be used to predict a person�??s risk for a particular disease and more effective than one or even several genes. One of the largest issues is the fear and potential consequences for patients who are predisposed after genetic testing or found to be non-responsive towards certain treatments. This includes the nutrition, life style, job effects on patients due to genetic testing results. The right of family members who do not directly consent is another issue, considering that genetic predispositions and risks are inheritable. The implications for certain ethnic groups and presence of a common allele would also have to be considered. We received the whole information of patients with NSCLC. According to this survey, that NSCLC is a multi factorial disease and related to epigenetic, if we want to predict the risks of the disease, we need to know more about the effects, life style and the personal behaviors more than the genetic and directly exposed parameters. Maybe in future, we can say there is difference for description of disease based on personal life and epigenetic.

Biography :

Seyedeh Afrooz Azimi has completed his PhD degree from Mashhad Medical University. She is the Quality Manager in Atieh Hospital in Tehran. She researches on NSCLC Diagnostic Biomarkers in Dr. Masih Daneshvari Hospital, Lung Center of Shahid Beheshti Medical University and she cooperates to published texts in scientific and research center.